Fund HoldingsAisling Capital Management LP

Total Portfolio Value
$359.67M
Total Bought
$2.25M
Total Sold
$0
Net Transaction
+$2.25M
Filing Period:
Securities
SharesValue ($K)
Q1 2025
Q2 2025
Change
Q1 2025
Q2 2025
Weight (%)
Change
BridgeBio Pharma Inc. (BBIO)(BBIO)6,068,1256,068,1250209,775262,02272.85%+52,247
Verona Pharma plc (VRNA)615,352615,352039,06958,20016.18%+19,131
Biomea Fusion Inc (BMEA)798,7572,048,757+1,250,0001,7013,6881.03%+1,986
Nuvation Bio Inc. (NUVB)(NUVB)2,541,0092,541,00904,4724,9551.38%+483
Elevation Oncology Inc (ELEV)2,834,9102,834,91007351,0410.29%+306
Marker Therapeutics, Inc. (MRKR)325,370325,37004004980.14%+98
Aclaris Therapeutics Inc (ACRS)434,455434,45506656170.17%-48
Compass Pathways Plc (CMPS)(CMPS)1,198,4181,198,41803,4273,3560.93%-72
CalciMedica, Inc. (CALC)521,114521,11409958340.23%-162
OnKure Therapeutics, Inc. (OKUR)88,60788,60703812120.06%-169
Monte Rosa Therapeutics Inc (GLUE)(GLUE)1,472,3311,472,33106,8326,6401.85%-191
Syndax Pharmaceuticals, Inc. (SNDX)(SNDX)1,025,0001,316,806+291,80612,58712,3253.43%-262
Bicara Therapeutics Inc. (BCAX)568,919568,91907,4135,2851.47%-2,128
Page 1 of 1